Latest News
StimLabs launches DermaForm collagen scaffold particulate device
4 November 2026 - Regenerative medicine company StimLabs announced on Tuesday the commercial launch of DermaForm, an FDA 510(k)-cleared porcine-derived particulate collagen scaffold that manages a range of acute and chronic wounds.DermaForm was devel...
Samsung Biologics awarded 'Negligible Risk' rating in Sustainalytics ESG assessment
4 November 2026 - Samsung Biologics (KRX:207940), a South Korea-based contract development and manufacturing organisation (CDMO), announced on Tuesday that it has achieved a 'Negligible Risk' rating in the latest Morningstar Sustainalytics ...
CStone and Kimia Therapeutics collaborate to advance oncology drug candidate
4 November 2026 - Chinese biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) announced on Tuesday that it has entered into a clinical collaboration agreement with US-based Kimia Therapeutics Inc, a biopharmaceutical company developing innov...
Moberg Pharma secures US patent for MOB-015 dosing regimen
3 November 2026 - Swedish pharmaceutical company Moberg Pharma AB (STO: MOB) on Tuesday said the United States Patent and Trademark Office has granted a patent covering an improved dosing regimen for MOB-015, its topical treatment for onychomycosis.T...
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
3 November 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that it has initiated ENHANCE-3, a Phase 3 clinical trial evaluating Ohtuvayre (ensifentrine) for preventing chron...